<DOC>
	<DOCNO>NCT00064064</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy gemcitabine use different way stop tumor cell divide stop grow die . 3-AP may stop growth tumor cell block enzymes necessary tumor cell growth may help gemcitabine kill cancer cell make sensitive drug . PURPOSE : Phase II trial study effectiveness combine gemcitabine 3-AP treating patient metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>3-AP Gemcitabine Treating Patients With Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine partial complete objective response rate patient metastatic non-small cell lung cancer treat 3-AP gemcitabine . - Determine progression-free overall survival patient treat regimen . - Determine safety regimen patient . OUTLINE : This multicenter study . Patients receive 3-AP IV 4 hour follow gemcitabine IV 30 minute weekly week 1-3 . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 22-50 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Metastatic disease Progressive disease 2 prior cytotoxic regimen contain least 1 follow drug : Cisplatin Carboplatin Taxane Vinorelbine Measurable disease No CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL ( transfusion allow ) Hepatic Bilirubin great 2.0 mg/dL ALT AST great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Chronic viral hepatitis allow Renal Creatinine great 2.0 mg/dL Cardiovascular No myocardial infarction within past 3 month No uncontrolled congestive heart failure No uncontrolled coronary artery disease No uncontrolled cardiac arrhythmia Pulmonary No dyspnea rest No supplemental oxygen dependence Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No active infection No prior concurrent malignancy except carcinoma situ cervix previously treat cone biopsy and/or resection , nonmetastatic basal cell squamous cell skin cancer , stage I malignancy curatively resect 5 year ago No concurrent lifethreatening illness PRIOR CONCURRENT THERAPY : Biologic therapy Prior noncytotoxic biologic regimens allow ( e.g. , vaccine , antibody , cytokine , small molecule cell signal inhibitor ) Chemotherapy See Disease Characteristics More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior gemcitabine No prior 3AP Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover Surgery More 3 week since prior surgery recover Other More 3 week since prior noncytotoxic regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>